nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Atrioventricular block complete—Lisinopril—dilated cardiomyopathy	0.0502	0.0589	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABCC9—dilated cardiomyopathy	0.047	0.664	CrCbGaD
Vidarabine—Drowsiness—Spironolactone—dilated cardiomyopathy	0.024	0.0282	CcSEcCtD
Vidarabine—Glucosamine—TNF—dilated cardiomyopathy	0.0238	0.336	CrCbGaD
Vidarabine—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.0229	0.0269	CcSEcCtD
Vidarabine—Lightheadedness—Furosemide—dilated cardiomyopathy	0.0209	0.0245	CcSEcCtD
Vidarabine—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.0198	0.0232	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.0194	0.0228	CcSEcCtD
Vidarabine—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.0175	0.0206	CcSEcCtD
Vidarabine—Discomfort—Spironolactone—dilated cardiomyopathy	0.0158	0.0185	CcSEcCtD
Vidarabine—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.0157	0.0184	CcSEcCtD
Vidarabine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.0153	0.018	CcSEcCtD
Vidarabine—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.014	0.0164	CcSEcCtD
Vidarabine—Somnolence—Spironolactone—dilated cardiomyopathy	0.0136	0.016	CcSEcCtD
Vidarabine—Pollakiuria—Furosemide—dilated cardiomyopathy	0.0135	0.0159	CcSEcCtD
Vidarabine—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.0134	0.0158	CcSEcCtD
Vidarabine—Drowsiness—Furosemide—dilated cardiomyopathy	0.0131	0.0153	CcSEcCtD
Vidarabine—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.013	0.0152	CcSEcCtD
Vidarabine—Sweating—Furosemide—dilated cardiomyopathy	0.0125	0.0147	CcSEcCtD
Vidarabine—Urticaria—Spironolactone—dilated cardiomyopathy	0.0122	0.0143	CcSEcCtD
Vidarabine—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.0121	0.0142	CcSEcCtD
Vidarabine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.0113	0.0132	CcSEcCtD
Vidarabine—Tinnitus—Furosemide—dilated cardiomyopathy	0.0109	0.0128	CcSEcCtD
Vidarabine—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.0108	0.0127	CcSEcCtD
Vidarabine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.0105	0.0123	CcSEcCtD
Vidarabine—Dizziness—Spironolactone—dilated cardiomyopathy	0.0101	0.0119	CcSEcCtD
Vidarabine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.01	0.0117	CcSEcCtD
Vidarabine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00974	0.0114	CcSEcCtD
Vidarabine—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00967	0.0113	CcSEcCtD
Vidarabine—Rash—Spironolactone—dilated cardiomyopathy	0.00966	0.0113	CcSEcCtD
Vidarabine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00965	0.0113	CcSEcCtD
Vidarabine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00963	0.0113	CcSEcCtD
Vidarabine—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00961	0.0113	CcSEcCtD
Vidarabine—Headache—Spironolactone—dilated cardiomyopathy	0.0096	0.0113	CcSEcCtD
Vidarabine—Sweating—Lisinopril—dilated cardiomyopathy	0.0094	0.011	CcSEcCtD
Vidarabine—Agitation—Furosemide—dilated cardiomyopathy	0.00939	0.011	CcSEcCtD
Vidarabine—Nausea—Spironolactone—dilated cardiomyopathy	0.0091	0.0107	CcSEcCtD
Vidarabine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00896	0.0105	CcSEcCtD
Vidarabine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00851	0.00998	CcSEcCtD
Vidarabine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00834	0.00978	CcSEcCtD
Vidarabine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00821	0.00963	CcSEcCtD
Vidarabine—Shock—Furosemide—dilated cardiomyopathy	0.0082	0.00962	CcSEcCtD
Vidarabine—Flushing—Lisinopril—dilated cardiomyopathy	0.00817	0.00958	CcSEcCtD
Vidarabine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00806	0.00945	CcSEcCtD
Vidarabine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00794	0.00931	CcSEcCtD
Vidarabine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00787	0.00923	CcSEcCtD
Vidarabine—Hypotension—Furosemide—dilated cardiomyopathy	0.00779	0.00914	CcSEcCtD
Vidarabine—Tension—Lisinopril—dilated cardiomyopathy	0.00752	0.00882	CcSEcCtD
Vidarabine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00751	0.0088	CcSEcCtD
Vidarabine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00749	0.00878	CcSEcCtD
Vidarabine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00744	0.00873	CcSEcCtD
Vidarabine—Back pain—Lisinopril—dilated cardiomyopathy	0.00741	0.0087	CcSEcCtD
Vidarabine—Somnolence—Furosemide—dilated cardiomyopathy	0.00741	0.00869	CcSEcCtD
Vidarabine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00722	0.00847	CcSEcCtD
Vidarabine—Tremor—Lisinopril—dilated cardiomyopathy	0.00718	0.00842	CcSEcCtD
Vidarabine—Pain—Furosemide—dilated cardiomyopathy	0.00713	0.00836	CcSEcCtD
Vidarabine—Angioedema—Lisinopril—dilated cardiomyopathy	0.007	0.00821	CcSEcCtD
Vidarabine—Syncope—Lisinopril—dilated cardiomyopathy	0.00687	0.00806	CcSEcCtD
Vidarabine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00677	0.00794	CcSEcCtD
Vidarabine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00674	0.0079	CcSEcCtD
Vidarabine—Cough—Lisinopril—dilated cardiomyopathy	0.00669	0.00785	CcSEcCtD
Vidarabine—Urticaria—Furosemide—dilated cardiomyopathy	0.00662	0.00777	CcSEcCtD
Vidarabine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00653	0.00765	CcSEcCtD
Vidarabine—Anxiety—Lisinopril—dilated cardiomyopathy	0.0065	0.00763	CcSEcCtD
Vidarabine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00645	0.00756	CcSEcCtD
Vidarabine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00638	0.00749	CcSEcCtD
Vidarabine—ADK—Purine metabolism—GPX1—dilated cardiomyopathy	0.00628	0.082	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00626	0.00734	CcSEcCtD
Vidarabine—Shock—Lisinopril—dilated cardiomyopathy	0.00615	0.00722	CcSEcCtD
Vidarabine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00614	0.0072	CcSEcCtD
Vidarabine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00611	0.00716	CcSEcCtD
Vidarabine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00605	0.00709	CcSEcCtD
Vidarabine—Asthenia—Furosemide—dilated cardiomyopathy	0.00598	0.00702	CcSEcCtD
Vidarabine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00585	0.00686	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00574	0.075	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.0057	0.00668	CcSEcCtD
Vidarabine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00562	0.00659	CcSEcCtD
Vidarabine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00558	0.00654	CcSEcCtD
Vidarabine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00556	0.00652	CcSEcCtD
Vidarabine—Dizziness—Furosemide—dilated cardiomyopathy	0.00551	0.00647	CcSEcCtD
Vidarabine—Pain—Lisinopril—dilated cardiomyopathy	0.00535	0.00627	CcSEcCtD
Vidarabine—Vomiting—Furosemide—dilated cardiomyopathy	0.0053	0.00622	CcSEcCtD
Vidarabine—Rash—Furosemide—dilated cardiomyopathy	0.00526	0.00617	CcSEcCtD
Vidarabine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00525	0.00616	CcSEcCtD
Vidarabine—Headache—Furosemide—dilated cardiomyopathy	0.00522	0.00613	CcSEcCtD
Vidarabine—Urticaria—Lisinopril—dilated cardiomyopathy	0.00497	0.00583	CcSEcCtD
Vidarabine—Nausea—Furosemide—dilated cardiomyopathy	0.00495	0.00581	CcSEcCtD
Vidarabine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00461	0.00541	CcSEcCtD
Vidarabine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00449	0.00526	CcSEcCtD
Vidarabine—ADA—Purine metabolism—GPX1—dilated cardiomyopathy	0.00427	0.0557	CbGpPWpGaD
Vidarabine—Dizziness—Lisinopril—dilated cardiomyopathy	0.00414	0.00485	CcSEcCtD
Vidarabine—Vomiting—Lisinopril—dilated cardiomyopathy	0.00398	0.00467	CcSEcCtD
Vidarabine—Rash—Lisinopril—dilated cardiomyopathy	0.00394	0.00463	CcSEcCtD
Vidarabine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00394	0.00462	CcSEcCtD
Vidarabine—Headache—Lisinopril—dilated cardiomyopathy	0.00392	0.0046	CcSEcCtD
Vidarabine—Nausea—Lisinopril—dilated cardiomyopathy	0.00372	0.00436	CcSEcCtD
Vidarabine—DPP4—Peptide hormone metabolism—ACE—dilated cardiomyopathy	0.00332	0.0433	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.0033	0.0431	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00315	0.0412	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—FAS—dilated cardiomyopathy	0.00269	0.0352	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—AGT—dilated cardiomyopathy	0.0022	0.0288	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00214	0.028	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—AGT—dilated cardiomyopathy	0.0021	0.0275	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—FAS—dilated cardiomyopathy	0.00199	0.0259	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.00184	0.0241	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.00184	0.0241	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00182	0.0238	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00164	0.0214	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.00129	0.0168	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ANKRD1—dilated cardiomyopathy	0.00124	0.0162	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.00124	0.0162	CbGpPWpGaD
Vidarabine—ADK—Metabolism—TAZ—dilated cardiomyopathy	0.00117	0.0152	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SDHA—dilated cardiomyopathy	0.00105	0.0138	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.001	0.0131	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—TNF—dilated cardiomyopathy	0.000998	0.013	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000941	0.0123	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ANKRD1—dilated cardiomyopathy	0.000843	0.011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.000795	0.0104	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TAZ—dilated cardiomyopathy	0.000793	0.0104	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000766	0.01	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.000726	0.00948	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SDHA—dilated cardiomyopathy	0.000717	0.00936	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000712	0.0093	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00069	0.00901	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000657	0.00857	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000657	0.00857	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—ACE—dilated cardiomyopathy	0.000627	0.00818	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00061	0.00797	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000591	0.00772	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000589	0.00769	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000559	0.0073	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000541	0.00706	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000505	0.00659	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.0005	0.00653	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.0005	0.00653	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000479	0.00625	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000465	0.00607	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00045	0.00588	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RAC1—dilated cardiomyopathy	0.0004	0.00522	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000397	0.00519	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000384	0.00502	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000365	0.00476	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000355	0.00464	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000345	0.0045	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GPX1—dilated cardiomyopathy	0.000287	0.00374	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000283	0.00369	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000283	0.00369	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CD36—dilated cardiomyopathy	0.000279	0.00364	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000271	0.00353	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000265	0.00346	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000263	0.00343	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000257	0.00335	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000257	0.00335	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000254	0.00332	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AGT—dilated cardiomyopathy	0.000251	0.00328	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000239	0.00311	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000236	0.00309	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000231	0.00302	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000217	0.00284	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000206	0.00269	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000197	0.00258	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GPX1—dilated cardiomyopathy	0.000195	0.00254	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CD36—dilated cardiomyopathy	0.00019	0.00248	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000187	0.00244	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000182	0.00237	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AGT—dilated cardiomyopathy	0.000171	0.00223	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000171	0.00223	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00016	0.00209	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000153	0.002	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000152	0.00198	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000152	0.00198	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000145	0.0019	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000141	0.00184	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000139	0.00181	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000136	0.00178	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000117	0.00152	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000111	0.00144	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.64e-05	0.00126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.5e-05	0.00124	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	8.58e-05	0.00112	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGT—dilated cardiomyopathy	8.2e-05	0.00107	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.61e-05	0.000863	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	5.69e-05	0.000743	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.9e-05	0.00051	CbGpPWpGaD
